There are now seven biopharmaceutical companies with genetic-based programs targeting the root cause of Rett syndrome, including Taysha's, which has recently received approval to begin the first-ever gene replacement clinical trial. This town hall from April 13, 2022, covers what this means for our plan for a cure, including all of the factors that contribute to next steps.
